Molecular structure of Mefenamic acid, CAS Number: 61-68-7
Mefenamic acid (CAS 61-68-7)
See product citations (6)
Application:
Mefenamic acid is a compound with antiproliferative activity against colorectal cancer cells
CAS Number:
61-68-7
Purity:
≥98%
Molecular Weight:
241.29
Molecular Formula:
C15H15NO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Mefenamic acid functions as an inhibitor of prostaglandin synthesis. It exerts its mechanism of action by inhibiting the activity of the enzyme cyclooxygenase, specifically the COX-1 and COX-2 isoenzymes. By doing so, it interferes with the conversion of arachidonic acid to prostaglandin precursors, ultimately reducing the production of prostaglandins. This inhibition leads to a decrease in the inflammatory response. At the molecular level, mefenamic acid interacts with specific enzymes and substrates involved in the inflammatory response.
Mefenamic acid (CAS 61-68-7) References
- Immunomodulatory activity of mefenamic acid in mice models of cell-mediated and humoral immunity. | Shabbir, A., et al. 2016. Indian J Pharmacol. 48: 172-8. PMID: 27127320
- Biodegradability of fluoxetine, mefenamic acid, and metoprolol using different microbial consortiums. | Velázquez, YF. and Nacheva, PM. 2017. Environ Sci Pollut Res Int. 24: 6779-6793. PMID: 28091995
- Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis. | Aguiar, GC., et al. 2016. Int J Exp Pathol. 97: 438-446. PMID: 28370591
- Mefenamic Acid Attenuates Chronic Alcohol Induced Cognitive Impairment in Zebrafish: Possible Role of Cholinergic Pathway. | Rajesh, V., et al. 2018. Neurochem Res. 43: 1392-1404. PMID: 29796737
- Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property. | Patel, SS., et al. 2020. Anticancer Agents Med Chem. 20: 998-1008. PMID: 32294047
- Mefenamic acid can attenuate depressive symptoms by suppressing microglia activation induced upon chronic stress. | Feng, X., et al. 2020. Brain Res. 1740: 146846. PMID: 32325074
- Improving Consistency for a Mefenamic Acid Immediate Release Formulation. | Prasad, E., et al. 2020. J Pharm Sci. 109: 3462-3470. PMID: 32853635
- Solubility enhancement of mefenamic acid by inclusion complex with β-cyclodextrin: in silico modelling, formulation, characterisation, and in vitro studies. | Sid, D., et al. 2021. J Enzyme Inhib Med Chem. 36: 605-617. PMID: 33557644
- Inflammasome, Inflammation, Infection and Mefenamic Acid. | Kasture, P., et al. 2022. J Assoc Physicians India. 70: 11-12. PMID: 35438288
- Mitochondrial protective effects caused by the administration of mefenamic acid in sepsis. | Dominguini, D., et al. 2022. J Neuroinflammation. 19: 268. PMID: 36333747
- Prediction of Mefenamic Acid Crystal Shape by Random Forest Classification. | Nakapraves, S., et al. 2022. Pharm Res. 39: 3099-3111. PMID: 36534313
- Anticancer Activity of 3,5-Bis(dodecyloxy)Benzoate-PAMAM Conjugates with Indomethacin or Mefenamic Acid. | Castillo-Rodríguez, IO., et al. 2023. Med Chem. 19: 460-467. PMID: 36573049
- Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. | Hixson, LJ., et al. 1994. Cancer Epidemiol Biomarkers Prev. 3: 433-8. PMID: 7920212
Inhibitor of:
AKR1C12, AKR1C13, AKR1C19, AKR1C20, AKR1CL1, AKR1CL2, AOX1, ASIC-β, ASIC4, Barttin, CatSperδ, CLC-2, CLC-3, CLC-6, connexin (GJA; gap junction), connexin 23, connexin 39, connexin 46, connexin 47, connexin 59, HS3ST3B1, HS3ST4, Iba1, PRRT3, Slc22a27, SLC26A8, SULT1B1, SULT2A2, and UGT2B1.Activator of:
AKR1C6, FMO3, GLOD5, and Peroxin 3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mefenamic acid, 25 g | sc-205380 | 25 g | $106.00 | |||
Mefenamic acid, 100 g | sc-205380A | 100 g | $208.00 |